Fånga sommarkänslan! Välj bland 1 miljon stories och känn sommarvibbarna. Från 49,50 kr/månad. Avsluta när du vill
Starta erbjudandetEkonomi & Business
The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.
The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.
Read more here: Moderna’s Covid vaccine offers vindication of its unconventional approach
Review clips: Yahoo Finance, CNBC
Hosted on Acast. See acast.com/privacy for more information.
Utgivningsdatum
Ljudbok: 2 december 2020
Ekonomi & Business
The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.
The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.
Read more here: Moderna’s Covid vaccine offers vindication of its unconventional approach
Review clips: Yahoo Finance, CNBC
Hosted on Acast. See acast.com/privacy for more information.
Utgivningsdatum
Ljudbok: 2 december 2020
Kliv in i en oändlig värld av stories
Inga recensioner ännu
Ladda ner appen för att vara med i snacket och lämna recensioner.
Svenska
Sverige